The POWER BARIATRIC Trial: Physical Outcomes With Exercise Regimens on BARIATRIC Patients

Overview

This study aims to determine how different types of exercise regimens (resistance, aerobic, or combined exercise regimens) can be used to minimize muscle loss and mobilize body fat in severely obese patients after bariatric surgery (BS), despite the rapid surgery-induced weight loss. Additionally, the study will examine how changes in the intestinal microbiota following BS act as a mediation factor that alter tissue-specific responses in muscle and adipose tissue. The study will also evaluate the effect of different types of exercise regimens on cardiometabolic markers, endocrine response, and physical function following BS. Sixty sedentary (regular exercise <1 hour per week) candidates to bariatric surgery at Herzliya Medical Center will be recruited to participate in this six-month-long randomized control study. Participants will be randomly assigned to either one of three exercise regimens intervention groups (aerobic, resistance, or a combined exercise regimen combining aerobic and resistance exercises) or a control group that will receive standard care. Training will be supervised and matched for metabolic equivalent (METs). The intervention will take place at the Sylvan Adams Sports Institute at Tel Aviv University and an online platform. All measurements will be taken at a presurgical baseline assessment and throughout the study, and will include changes of muscle mass and adipose tissue distribution, measured by a 3-Tesla magnetic resonance imaging (MRI); body composition- will be assessed using multichannel bioelectrical impedance (Seca); Bone mass, will be measured by a Dual-energy X-ray absorptiometry (DEXA); microbiota composition and changes will be evaluated by stool samples that will be subjected to 16S ribosomal ribonucleic acid (16s rRNA) profiling and metagenomics analysis; fasting blood samples will be used to examine endocrine control and cardiometabolic markers; anthropometric measurements to assess surgery results associations with physical activity outcomes and physical function will be assessed by several validated performance assessments, including handgrip, six-minute walk, sit-to-stand, maximum voluntary contraction, and maximal oxygen consumption (VO2max).

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 30, 2024

Detailed Description

The primary aim will be to determine how different types of exercise regimens (resistance, aerobic, or combined exercise regimens) can be used to minimize muscle loss and mobilize body fat in severely obese patients after BS, despite the rapid surgery-induced weight loss. Secondary aims will include: I. To examine the effect of different exercise regimens on the composition and diversity of microbiomes, and their role in mediating muscle mass preservation following BS. II.Evaluate changes in cardiometabolic markers and endocrine response to different exercise regimens and evaluates microbiome mediation of these changes after BS. III.Assess the effect of different exercise regimens on physical function among patients following BS. IV.Clarify the mechanisms of muscle preservation and fat loss involving hormonal response and atrophy related-genes expression. After baseline measurements (detailed below), participants will be randomized into one of four groups: 1. control group (n=15) that includes routine health care; 2. aerobic exercise training group (n=15), 3. resistance exercise training group (n=15), 4. combined aerobic and resistance exercise training group (n=15). Training sessions will be both in-person and as online exercise supervision. All groups will be supported by a dietitian as part of the routine health care after the bariatric surgery. The dietetic program for all groups will consist of a balanced diet by diet progression guidelines for bariatric patients (XX,ZZ) and the bariatric food pyramid (55). The protein content will be a minimum of 60 gr/protein per day, according to current guidelines (XX,ZZ) . Each training session will increase gradually up to 60 minutes per session, three times a week. Participants will be randomized into 4 groups for 26 weeks of intervention including aerobic, resistance, combined exercise training (aerobic + resistance) and a control group without exercise training. All exercise training will be matched in metabolic equivalent (METs) and the time of training per week. Participants will begin a two weeks exercise adaptation period at 3-4 postoperative weeks. The activity adaptation plan will consist of 15-20 min. of walking, three times per week, at an intensity of 40-60% of peak oxygen consumption (VO2) or rate of perceived exertion (RPE) 4-6 on the Borg scale for all intervention groups. Following this period, each group will participate in a specific progressive training with the following regimen: 1. Aerobic exercise training group, weeks 5-8 after surgery: this training will consist of 30 min. of walking, 3 times per week at an intensity of 60-70% of peak VO2 or RPE 6-7 on Borg scale. Weeks 9-26 after surgery: this training will consist of 60 minutes of exercise, 3 times per week at an intensity of 65-80% of peak VO2 or RPE 6-8 on the Borg scale. The aerobic exercises will consist of a treadmill or outside walking or running, stationary cycling or elliptical trainer in continuous and interval training. 2. Resistance exercise training group, weeks 5-8 after surgery: this training will consist of 5-10 minutes of warmup, followed by 6-8 multi-joint exercises for major muscle groups, comprising 2 sets of 10 to 25 repetitions at 40% of the one-repetition maximum (1-RM) for each exercise. The intensity will increase on weeks 9-26 after surgery to 8-10 multi-joint exercises of 3-4 sets of 10 to 25 repetitions. For this training participants will use free-weights and bodyweight exercises. 3. The combination exercise training will consist of a combined aerobic and resistance exercise training sessions three times weekly. At weeks 5-8 after surgery, the sessions will include 5-10 minutes of warmup, followed by 3-4 multi-joint exercises for major muscle groups, comprising 2 sets of 10 to 25 repetitions at 40% of the one-repetition maximum (1-RM) for each exercise. Afterward, the aerobic part of the training will consist of 10-15 minutes of aerobic exercises (treadmill or outside walking or running, stationary cycling or outdoors or elliptical trainer) at 60-70% of peak VO2 or RPE 6-7 at Borg scale. The intensity will increase on weeks 9-26 after surgery to 4-5 multi-joint exercises of 3-4 sets of 10 to 25 repetitions and 30 minutes of aerobic exercises at 65-80% of peak VO2 or RPE 6-8 at Borg scale. 4. The control group will receive conventional treatment so as the other groups (medical and nutritional follow up).

Interventions

  • Other: Physical activity training
    • Participants will be randomized into either one of three intervention groups (aerobic training, resistance training, or combined training comprised of resistance and aerobic training) and a control group. Training is described in the arm description section.

Arms, Groups and Cohorts

  • Experimental: Aerobic exercise training
    • The aerobic exercise training group, weeks 5-8 after surgery: this training will consist of 30 min. of walking, 3 times per week at an intensity of 60-70% of peak VO2 or RPE 6-7 on the Borg scale. Weeks 9-26 after surgery: this training will consist of 60 minutes of exercise, 3 times per week at an intensity of 65-80% of peak VO2 or RPE 6-8 on the Borg scale. The aerobic exercises will consist of a treadmill or outside walking or running, stationary cycling or elliptical trainer in continuous and interval training.
  • Experimental: Resistance exercise training
    • Resistance exercise training group, weeks 5-8 after surgery: this training will consist of 5-10 minutes of warmup, followed by 6-8 multi-joint exercises for major muscle groups, comprising 2 sets of 10 to 25 repetitions at 40% of the one-repetition maximum (1-RM) for each exercise. The intensity will increase on weeks 9-26 after surgery to 8-10 multi-joint exercises of 3-4 sets of 10 to 25 repetitions. For this training participants will use free-weights and body weight exercises.
  • Experimental: Combination exercise training
    • The combination exercise training will consist of a combined aerobic and resistance exercise training sessions three times weekly. At weeks 5-8 after surgery the sessions will include 5-10 minutes of warmup, followed by 3-4 multi-joint exercises for major muscle groups, comprising 2 sets of 10 to 25 repetitions at 40% of the one-repetition maximum (1-RM) for each exercise. Afterwards the aerobic part of the training will consist of 10-15 minutes of aerobic exercises (treadmill or outside walking or running, stationary cycling or outdoors or elliptical trainer) at 60-70% of peak VO2 or RPE 6-7 at Borg scale. The intensity will increase on weeks 9-26 after surgery to 4-5 multi-joint exercises of 3-4 sets of 10 to 25 repetitions and 30 minutes of aerobic exercises at 65-80% of peak VO2 or RPE 6-8 at Borg scale.
  • No Intervention: The control group
    • The control group will receive routine health care without exercise supervision (clinical and nutritional follow up).

Clinical Trial Outcome Measures

Primary Measures

  • Muscle mass (cm3)
    • Time Frame: At baseline and after 26 weeks of intervention
    • Changes in thigh muscles volume
  • Body composition – fat mass
    • Time Frame: At baseline and after 13 and 26 weeks of intervention
    • Fat mass (Kg)
  • Body composition
    • Time Frame: At baseline and after 13 and 26 weeks of intervention
    • Fat free mass (Kg)

Secondary Measures

  • Microbial composition and changes
    • Time Frame: At baseline and after 13 and 26 weeks of intervention
    • 16S rRNA profiling
  • Blood measurements – cardiometabolic markers
    • Time Frame: At baseline and after 13 and 26 weeks of intervention
    • Cardiometabolic markers: Glucose (mg/dl), lipid profile (total cholesterol in mg/dl, HDL in mg/dl, LDL in mg/dl)
  • Blood measurements – Insulin
    • Time Frame: At baseline and after 13 and 26 weeks of intervention
    • Insulin (pmol/L)
  • Blood measurements for skeletal muscle metabolism assessment
    • Time Frame: At baseline and after 13 and 26 weeks of intervention
    • Levels of anabolic hormones such as growth hormone (ng/ml) (GH), insulin like growth factor (ng/ml) (IGF-1). Marker of inhibition of skeletal muscle growth: Myostatin (ng/ml)
  • Blood measurements – Inflammatory markers
    • Time Frame: At baseline and after 13 and 26 weeks of intervention
    • Interleukin-6 (pg/ml) (IL6)
  • Blood measurements for nutritional status
    • Time Frame: At baseline and after 13 and 26 weeks of intervention
    • Markers for nutritional status: Hemoglobin (g/dl), albumin (g/dl)
  • Blood measurements for micronutrients
    • Time Frame: At baseline and after 13 and 26 weeks of intervention
    • Ferritin (ng/ml), B12 (ng/ml)
  • Blood measurements for liver function
    • Time Frame: At baseline and after 13 and 26 weeks of intervention
    • Liver enzymes: alanine aminotransferase in units per liter (U/L) (AST), gamma-glutamyltransferase (U/L)(GGT), alanine aminotransferase (U/L) (ALT), alkaline phosphatase (U/L) (ALP);
  • Blood measurements of adipokines – leptin
    • Time Frame: At baseline and after 13 and 26 weeks of intervention
    • Leptin (ng/ml)
  • Blood measurements of adipokines – adiponectin
    • Time Frame: At baseline and after 13 and 26 weeks of intervention
    • Adiponectin (μg/ml)
  • Blood measurements for bone status
    • Time Frame: At baseline and after 13 and 26 weeks of intervention
    • Blood bone markers such as Collagen Type-1 C-Telopeptide in μg/L (CTX) and total procollagen type 1 N-terminal propeptide in μg/L (P1NP).
  • Bone density changes
    • Time Frame: At baseline and after 13 and 26 weeks of intervention
    • Assessed by DEXA scan (T score and g/cm^2)
  • Anthropometric measurements – BMI
    • Time Frame: At baseline and after 13 and 26 weeks of intervention
    • Weight (kg) and height (m) will be combined to calculate BMI (kg/m^2)
  • waist circumference as part of Anthropometric measurements
    • Time Frame: At baseline and after 13 and 26 weeks of intervention
    • waist circumference (cm)
  • Weight loss percentage outcomes
    • Time Frame: At baseline and after 13 and 26 weeks of intervention
    • % Excess weight loss (%EWL) will be calculated by [(initial weight (kg))-(post operative weight(kg))] / [(initial weight in kg) – (ideal body weight in kg)]. Total weight loss % (TWL%) will be calculated by [(initial weight (kg))-(post operative weight(kg))] / initial weight (kg).
  • Resting metabolic rate
    • Time Frame: At baseline and after 13 and 26 weeks of intervention
    • measurement of resting daily energy expenditure (Kcal) will be measured by indirect calorimetry (Kcal/day) and energy expenditure per body kilogram per day (Kcal/Kg/day).

Participating in This Clinical Trial

Inclusion Criteria

  • Sedentary participants: regular exercise performed <1 hour per week – Candidates for primary bariatric surgery at Herzliya Medical Center in accordance to the National Institutes of Health (NIH) criteria for surgery: (body mass index (BMI) > 40 without coexisting co-morbidities or BMI > 35 with > 1 severe obesity-related comorbidities) – Sex: all – Age: 18 to 65 years. Exclusion Criteria:

  • Severe cardiopulmonary disease (e.g., recent myocardial infarction or unstable angina) – Musculoskeletal or neuromuscular impairments that preclude exercise training – Cognitive impairments – Use of drugs that affect bone or muscle metabolism (mainly steroids) – Patients with previous bariatric surgery

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Tel Aviv University
  • Collaborator
    • Herzliya Medical Center
  • Provider of Information About this Clinical Study
    • Principal Investigator: Gepner Yftach, Dr. Gepner Yftach – Tel Aviv University
  • Overall Official(s)
    • Yftach Gepner, Ph.D., Principal Investigator, Tel Aviv University
  • Overall Contact(s)
    • Yftach Gepner, Ph.D., +972733804726, gepner@tauex.tau.ac.il

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.